SCHEMBL4370392

SCHEMBL4370392

Cn1cncc1C(O)(c1ccc(Cl)cc1)c1ccc2c(c1)C(c1cccc(Cl)c1)SCC(NN)=N2

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FNTA P49354 8/20 0.57
FNTB P49356 8/20 0.57
RORC P51449 9/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4373656 0.81 FNTA (0.82) FNTAFNTBRORC
SCHEMBL4384908 0.81 FNTA (0.55) FNTAFNTBRORC
SCHEMBL4373631 0.81 FNTA (0.59) FNTAFNTBRORC
SCHEMBL4382829 0.79 FNTA (0.62) FNTAFNTBRORC
SCHEMBL4377464 0.79 FNTA (0.45) FNTAFNTB
SCHEMBL4375776 0.77 FNTA (0.65) FNTAFNTBRORC
SCHEMBL4372438 0.73 FNTA (1.00) FNTAFNTB
SCHEMBL1683552 0.73 FNTA (0.49) FNTAFNTBRORC
SCHEMBL5513838 0.72 FNTA (0.60) FNTAFNTBRORC
SCHEMBL3554724 0.71 FNTA (0.50) FNTAFNTBRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339709-B1 FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 EP disclosed
US-7153958-B2 Farnesyl transferase inhibiting benzoheterocyclic derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-26 US disclosed
US-20040034218-A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2004-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034218-A1 Farnesyl transferase inhibiting benzoheterocyclic derivatives FNTA, FNTB, RCE1 FNTA 1/4885FNTB 2/4885RORC 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.